Merus NV (NASDAQ:MRUS) Expected to Post Earnings of -$0.54 Per Share

Brokerages expect Merus NV (NASDAQ:MRUS) to report earnings of ($0.54) per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Merus’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.46). Merus reported earnings of ($0.60) per share during the same quarter last year, which would indicate a positive year over year growth rate of 10%. The company is scheduled to report its next earnings results on Thursday, July 25th.

On average, analysts expect that Merus will report full-year earnings of ($1.90) per share for the current fiscal year, with EPS estimates ranging from ($2.19) to ($1.72). For the next year, analysts forecast that the company will post earnings of ($1.77) per share, with EPS estimates ranging from ($2.29) to ($1.47). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Merus.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, May 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.22. The firm had revenue of $8.75 million during the quarter, compared to analyst estimates of $7.47 million. Merus had a negative return on equity of 39.46% and a negative net margin of 75.71%.

A number of research firms have recently weighed in on MRUS. BidaskClub lowered Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 13th. Roth Capital raised their price objective on Franklin Covey from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Berenberg Bank lowered their price objective on Lucara Diamond from C$1.60 to C$1.50 in a research report on Wednesday, March 27th. Zacks Investment Research raised Jack Henry & Associates from a “sell” rating to a “hold” rating in a research report on Wednesday, March 27th. Finally, Guggenheim cut Anadarko Petroleum from a “buy” rating to a “hold” rating and set a $69.00 price target for the company. in a research report on Friday, April 12th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Merus currently has an average rating of “Buy” and an average price target of $22.57.

Shares of NASDAQ MRUS traded up $0.03 during mid-day trading on Wednesday, reaching $15.03. The company’s stock had a trading volume of 4 shares, compared to its average volume of 29,490. The company has a market cap of $341.58 million, a price-to-earnings ratio of -8.16 and a beta of 0.22. The firm’s fifty day simple moving average is $14.21. Merus has a 52 week low of $11.00 and a 52 week high of $24.37.

A number of institutional investors and hedge funds have recently modified their holdings of MRUS. Squarepoint Ops LLC lifted its position in Merus by 10.3% during the 4th quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,100 shares during the period. Geode Capital Management LLC increased its holdings in Merus by 18.8% in the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 2,373 shares during the last quarter. Granite Investment Partners LLC purchased a new position in Merus in the first quarter valued at $468,000. Finally, Morgan Stanley increased its holdings in Merus by 74.3% in the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after buying an additional 30,538 shares during the last quarter. 52.13% of the stock is owned by institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

See Also: How does the Beige Book influence monetary policy?

Get a free copy of the Zacks research report on Merus (MRUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.